dc.contributor.author | Hanevik, Kurt | |
dc.contributor.author | Saghaug, Christina Skår | |
dc.contributor.author | Aaland, Maren | |
dc.contributor.author | Mørch, Kristine | |
dc.contributor.author | Langeland, Nina | |
dc.date.accessioned | 2022-09-30T11:40:07Z | |
dc.date.available | 2022-09-30T11:40:07Z | |
dc.date.created | 2022-04-03T19:07:26Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 2397-9070 | |
dc.identifier.uri | https://hdl.handle.net/11250/3022888 | |
dc.description.abstract | Background and Aim
Functional gastrointestinal disorders (FGIDs) and chronic fatigue syndrome (CFS) frequently occur as comorbid conditions to each other. A shared etiology of these syndromes has been proposed because of their shared symptomatology and triggering by infections. Antibodies against the bacterial antigens cytolethal distending toxin B (CdtB) and flagellin have been proposed to be biomarkers of irritable bowel syndrome (IBS), especially diarrhea-predominant IBS (IBS-D). It is unknown if they may also be associated with comorbid conditions such as CFS. On the other hand, elevated level of B-cell activating factor (BAFF) has been associated with CFS and inflammatory bowel disease (IBD) and subjective food intolerance.
Methods
We evaluated serum levels of anti-flagellin and anti-CdtB using an in-house enzyme-linked immunosorbent assay (ELISA) and BAFF with a commercially available ELISA kit in a cohort of patients who developed fatigue syndromes and/or FGIDs after Giardia infection, by comparing them with healthy controls without these conditions.
Results
We did not find significant differences in circulating BAFF, anti-CdtB, or anti-flagellin antibody levels in these patient groups compared to healthy controls. Therefore, our results do not support a role for BAFF, anti-CdtB, or anti-flagellin antibodies as universal biomarkers for IBS or CFS.
Conclusion
BAFF, anti-CdtB, or anti-flagellin antibodies cannot be considered as universal biomarkers for IBS or CFS. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1002/jgh3.12724 | |
dc.identifier.cristin | 2014913 | |
dc.source.journal | Journal of Gastroenterology and Hepatology Open (JGH Open) | en_US |
dc.source.pagenumber | 185-188 | en_US |
dc.identifier.citation | Journal of Gastroenterology and Hepatology Open (JGH Open). 2022, 6 (3), 185-188. | en_US |
dc.source.volume | 6 | en_US |
dc.source.issue | 3 | en_US |